Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
News|Articles|May 28, 2026
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
Author(s)Russ Conroy
Fact checked by: Roman Fabbricatore
Presentations at the 2026 ASCO Annual Meeting may reveal key advances in the use of different bispecific antibodies and CELMoDs in multiple myeloma care.
Advertisement
Advertisement
The
Related to this article
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Advertisement
Advertisement